DTC Comments Support FDA’s Goals; PhRMA Watching “Boundaries”
FDA should remove language in its "disease awareness" advertising guidance suggesting the agency can take action against sponsors of "help-seeking" ads if they are the only manufacturer of a product to treat the disease, the Pharmaceutical Research & Manufacturers of America said
More from Archive
More from Pink Sheet
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.